Reaction Details |
| Report a problem with these data |
Target | Mitogen-activated protein kinase 9 |
---|
Ligand | BDBM50215054 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_456441 (CHEMBL907530) |
---|
IC50 | 2±n/a nM |
---|
Citation | Moss, N; Breitfelder, S; Betageri, R; Cirillo, PF; Fadra, T; Hickey, ER; Kirrane, T; Kroe, RR; Madwed, J; Nelson, RM; Pargellis, CA; Qian, KC; Regan, J; Swinamer, A; Torcellini, C New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site. Bioorg Med Chem Lett17:4242-7 (2007) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Mitogen-activated protein kinase 9 |
---|
Name: | Mitogen-activated protein kinase 9 |
Synonyms: | JNK-55 | JNK2 | JNK2/JNK3 | MAPK9 | MK09_HUMAN | Mitogen-Activated Protein Kinase 9 (JNK2) | Mitogen-activated protein kinase 8/9 | PRKM9 | SAPK1A | Stress-activated protein kinase JNK2 | c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 2 (JNK2) |
Type: | Enzyme |
Mol. Mass.: | 48131.49 |
Organism: | Homo sapiens (Human) |
Description: | JNK-2 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology). |
Residue: | 424 |
Sequence: | MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRP
FQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIH
MELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNF
MMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQ
LGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSK
MLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEV
MDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPL
EGCR
|
|
|
BDBM50215054 |
---|
n/a |
---|
Name | BDBM50215054 |
Synonyms: | 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(6-(morpholinomethyl)pyridin-3-yl)naphthalen-1-yl)urea | CHEMBL381743 |
Type | Small organic molecule |
Emp. Form. | C35H38N6O2 |
Mol. Mass. | 574.7152 |
SMILES | Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(-c2ccc(CN3CCOCC3)nc2)c2ccccc12)C(C)(C)C |
Structure |
|